Skip to main content
Clinical Trials/NCT03434574
NCT03434574
Completed
Not Applicable

Evaluation of the Effect of Chokeberry (Aronia Melanocarpa) Polyphenols on Blood Pressure in Prehypertensive Healthy Men and Women

King's College London2 sites in 1 country102 target enrollmentFebruary 20, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prehypertension
Sponsor
King's College London
Enrollment
102
Locations
2
Primary Endpoint
Changes from baseline ambulatory blood pressure after 12-week consumption
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Aronia berries are a native North American berry with high naturally occurring anthocyanins among other polyphenols. Based on their polyphenol composition, there is growing interest in the potential for Aronia berries to elicit health promoting cardio-metabolic effects. Specifically, Aronia berry extracts, which provide a concentrated source of polyphenols, may improve blood vessel function.

Thus, the primary focus of this project is to evaluate the effects of Aronia berry polyphenols on blood pressure and other biomarkers of cardiovascular disease risk such as endothelial function, arterial stiffness and blood lipids.

Registry
clinicaltrials.gov
Start Date
February 20, 2018
End Date
September 12, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Ana Rodriguez-Mateos

Principal investigator

King's College London

Eligibility Criteria

Inclusion Criteria

  • Healthy men and women aged 40-70 years old
  • Blood pressure comprised between: SBP 120/139 mmHg or DBP 80/89 mmHg
  • Subjects are willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study
  • Are able to understand the nature of the study
  • Able and willing to give signed written informed consent
  • Signed informed consent form

Exclusion Criteria

  • Manifest cardiovascular disease including coronary artery disease, cerebrovascular disease and peripheral artery disease
  • Grade 1 hypertensive or above, as defined as SBP superior or equal to 140 mmHg or DBP superior or equal to 90 mmHg
  • Obese participants, defined as BMI superior or equal to 30
  • Diabetes mellitus and metabolic syndrome
  • Acute inflammation
  • Chronic and acute disease
  • Terminal renal failure and other kidney abnormalities
  • Malignancies
  • Abnormal heart rhythm
  • Allergies to berries or other significant food allergy.

Outcomes

Primary Outcomes

Changes from baseline ambulatory blood pressure after 12-week consumption

Time Frame: Baseline and 12 weeks

Determine the effect of the Aronia extract vs Placebo on ambulatory 24-hour systolic and diastolic blood pressure at 12 weeks post consumption, compared to the baseline.

Secondary Outcomes

  • Blood lipids(Baseline and 12 weeks)
  • Number of volunteers with treatment-related adverse events(Baseline and 12 weeks)
  • Blood flow velocity(Baseline 0 and 2 hours and 12 weeks 0 and 2 hours)
  • Pulse wave velocity (PWV)(Baseline 0 and 2 hours and 12 weeks 0 and 2 hours)
  • Heart rate(Baseline 0 and 2 hours and 12 weeks 0 and 2 hours)
  • Blood cortisol(Baseline and 12 weeks)
  • Augmentation Index (AIx)(Baseline 0 and 2 hours and 12 weeks 0 and 2 hours)
  • Office blood pressure(Baseline 0 and 2 hours and 12 weeks 0 and 2 hours)
  • Flow-mediated dilation(Baseline 0 and 2 hours and 12 weeks 0 and 2 hours)
  • 24-hour heart rate(Baseline and 12 weeks)

Study Sites (2)

Loading locations...

Similar Trials